Member Info for Bluebelly

I changed the title as it was drawing in the wrong characters. Wontogo: Good luck with EVE, I hope she/he is everything you wish for. Tils is now valued on it's pipeline of three, Accustem has nothing to do with TILS valuation. It was demerged to release it's value and we will find out that out shortly.

BB

A few statements are now out of date.
We know from the recent online document relating to the planned Covid trial:
https://clinicaltrials.gov/ct2/show/NCT04983446?spons=tiziana&draw=2&rank=1
It is no longer commencing in 3Q21, but Oct 21. It also states on page 5 of the presentation that the intranasal covid trial for phase 1 is completed & the next trial is being planned, yet the link above states:
'In a separate Phase 2 randomized, controlled, pilot trial conducted to assess safety, tolerability, and efficacy in 39 patients with mild to moderate COVID-19 in Brazil, showed that intranasal foralumab may be of benefit in modulating immune reactivity and in reducing pulmonary inflammation.'
This information is important for investors to see where the pipeline currently stands.

BB

'The Intertropical Convergence Zone, known by sailors as the doldrums or the calms because of its monotonous windless weather'.
Lets have some news to put the wind in our sails.
Two trades in 90 minutes trading. Hopefully the calm before the storm.
'Wheelhouse, half ahead both engines, 210 revolutions - Homeward bounders'

BB

Do Atlas believe they will get the others converted at a lower SP?
If so why convert the 100k?

BB

Agree Cloudy - From Link:
'In a separate Phase 2 randomized, controlled, pilot trial conducted to assess safety, tolerability, and efficacy in 39 patients with mild to moderate COVID-19 in Brazil, showed that intranasal foralumab may be of benefit in modulating immune reactivity and in reducing pulmonary inflammation. Importantly, intranasal administration of foralumab was well tolerated with no clinically significant changes in blood cell counts (including blood lymphocytes), no evidence of hypersensitivity, and no serious adverse events (SAEs) were reported in the study.'

BB

At least there's only 5 months of 2021 left.

BB

Thanks for that info vic960
Shame it's not starting until 25th Oct with study completion date of May 2022.
Is this because they wanted more data on Foralumab as stated by SJ1.
Hopefully the SPA data from the MS patient will give us a lift.

BB

Denny11, I believe that should have happened in H1 2021, however, they separated Accustem with £1m, so I don't believe they would have had the funds to do what was proposed. No information from TILS or via Accustem website. GC stated he had not recruited a Team to run Accustem around Mar/Apr 21. Hence my thoughts of 15 months with no progress.

BB

Thanks LBC, I read the SEC filing but couldn't see how the £1.50 issue price was confirmed anywhere. I believe they have the ADR's to issue at any price up to a value of $250m. Lets hope they will wait until TLSA is a hot stock and raise at a good price - Foralumab POC.

BB

Either way, Accustem valued @ 15p or 30p. The process to separate was due to no value being given to Accustem according to GC in a video chat.
The RNS dated, 22 May 20 stated ( Tils Closed @96p on that day - 27p higher than today):
'The rationale of this decision is that, as a standalone genomics-based personalized medicine company and separate legal entity, StemPrintER could:
· Secure separate financial resources, with the goal of enabling accelerated development of the StemPrintER genomic test:
· Separate StemPrintER from Tiziana's biotechnology and pharmaceutical businesses so it may focus on the personalized medicine market; and
· Allow Shareholders to benefit from both Tiziana's rapidly developing drug portfolio and the standalone value of StemPrintER as it progresses through its own development milestones and the path to commercialization and allow shareholders to receive the maximum potential value from StemPrintER as a standalone entity.'

Unfortunately, StemprintER has not progressed in the last 15 months, as far as we are aware.
However, TILS has progressed with various treatments and we are 27p lower than when the announcement was made. I'm still a believer of TILS, but Accustem is in danger of being over taken by advances in other diagnostic methods (blood testing etc) or even advances in treatments for Cancer.

BB

jh2704: My view is that we will run out of money in 12 to 18 months.
Tils state they are funded through 2022, but good practice is to have funds to see you through the next 12 months minimum. I imagine they will look to raise funds early next year after successful Foralumab trials to achieve POC .
They have ADR's on the shelf for up to $250m ready to go, there was talk of a price of £1.50 as the issue price, but I cannot find anything stating this. The SEC filing was late January 21.

BB

https://www.investopedia.com/terms/p/pinksheets.asp
Still no clearer, but its not an official listing. So are ADR's required, as they would be for an official listing.

BB

Are the OTC PK's trading ADR's or ordinary shares of Accustem Sciences Limited?
As Accustem are not yet listed are ADR's available?
Any holders of ADR's care to comment or explain what they have been given for their holding.

BB

Hi SK
I think there is still confusion here wrt Accustem shares. The SEC filing stated:
American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing two ordinary shares of Accustem Sciences Limited.
See Document link:
https://www.sec.gov/Archives/edgar/data/0001850767/000138713121006805/accu-f6_062221.htm
Everything has been unclear with the Accustem listing.

BB

Down from 300p, could a cheeky bid come in.
After 11th Aug it drops to 204p.
I guess they'd wait a few days to save £40m. Didn't GC turn down £3 , or was it just a rumour? But that did include Accustem, whatever the value of that is???

BB

I think we are over the hill now & need to let the BoD redeem themselves.
In January I wish I had bought more sub £1. The fall since Feb has allowed me to do that and gain a further 27,000 shares.
It's been a long six months and Accustem is another story!
Let's hope the news will come quick & fast in H2 as we move to comfirmation of Foralumab Proof of Concept.

BB

We have slipped behind the competition with the constant delays in our planned testing of the pipeline of treatments. Let's hope we come out on top at the end.

BB

'Phase 2 clinical trial for the nebulised treatment of COVID-19 patients using the novel SPC-069 formulation'Nebuliser Trials'
SpectrumX are also supporting the Medical University Hospital Innsbruck who are undertaking a Phase 2 clinical trial for the nebulised treatment of COVID-19 patients using the novel SPC-069 formulation. This is currently at IRB sign off stage and has been excellently developed by Professor Germar Pingerra who will be leading the trial.

Nebulisers are medical devices that enable deposition (the dispersion and planting of water vapour and/or nebulised medication) into the deeper areas of the respiratory system, such as the lung tissue, this is a key treatment pathway for COVID-19.

The primary end points of the studies we hope to demonstrate is that inflammation symptoms are reduced, patients breathe easier after treatment, and the recovery times and reversal of symptoms happens within 2-5 days. Other benefits may include reduction of the viral load in the respiratory system, making it harder to transmit it to others. Many of the patients who contract COVID-19 also develop bacterial pneumonia. We believe that it may be possible to mitigate the pneumonia during nebulizing SPC-069 into the lung for the therapeutic treatment of COVID-19.

The focus of the trial is to establish that the use of the product can dramatically reduce hospitalisation stays for patients suffering from COVID-19. This is of particular interest because unlike vaccines, which may become ineffective against future variants of COVID-19, SPC-069 will be efficacious against all mutations of the viral infection. '
Competition!!
BB

A couple of posts from telegram:
https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-joint-procurement-agreement-with-european-commission-for-covid-19-treatment-sotrovimab/

Also dosing via IV = IV infusion of sotrovimab 500 mg vs intranasal Foralumab 100 µg for 14 days. 350 times larger dose used by sotrovimab, a lot of which goes to unaffected areas, so more risk of side effects. Foralumab will be the Holy Grail when it gets more coverage.

BB

https://www.cnbc.com/quotes/ACMSY?qsearchterm=acmsy
No real volume.
I don't know how many have access to the Pinks.

BB